10-Year Data From CheckMate 067 Confirms Survival Advantage of Nivolumab in Advanced ...
Nivolumab (Opdivo) with or without ipilimumab (Yervoy) significantly improved 10-year overall and melanoma-specific survival in advanced melanoma patients compared to ipilimumab alone, according to the CheckMate 067 trial. The 10-year overall survival rates were 43%, 37%, and 19% for nivolumab/ipilimumab, nivolumab monotherapy, and ipilimumab monotherapy, respectively.
Related Clinical Trials
Reference News
10-Year Data From CheckMate 067 Confirms Survival Advantage of Nivolumab in Advanced ...
Nivolumab (Opdivo) with or without ipilimumab (Yervoy) significantly improved 10-year overall and melanoma-specific survival in advanced melanoma patients compared to ipilimumab alone, according to the CheckMate 067 trial. The 10-year overall survival rates were 43%, 37%, and 19% for nivolumab/ipilimumab, nivolumab monotherapy, and ipilimumab monotherapy, respectively.